Skip to content
Disclosery

Merck & Co., Inc.

Follow

13F filer, CIK 310158, RAHWAY, NJ

Merck & Co., Inc. reported $526,407,169 across 13 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-07. Its ten largest share positions make up 99.79% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000310158-26-000210

Period
2026-06-30
Reported value
$526M
Holdings
13
Top 10 weight
99.79%
New
3
Sold out
4

Part of the filer group Merck & Co., Inc.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TRDAnew+1,739,768$12.8M
STROnew+272,351$9.04M
EVAXnew+1,214,126$3.76M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ENTRADA THERAPEUTICS INCexited-1,739,768-$22M
SUTRO BIOPHARMA INCexited-272,351-$6.78M
EVAXION BIOTECH A/Sexited-1,214,126-$4.52M
CARMexited-1,473,240-$47.9K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0000310158-26-000210, largest first. % of portfolio is the value over $526,407,169, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PSNLPERSONALIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 14,044,943 shares; 2025Q1: 14,044,943 shares; 2025Q2: 14,044,943 shares; 2025Q3: 14,044,943 shares; 2025Q4: 14,044,943 shares; 2026Q1: 14,044,943 shares; 2026Q2: 14,044,943 shares 14,044,943$188M35.75%0Timeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 2,308,190 shares; 2025Q1: 2,308,190 shares; 2025Q2: 2,308,190 shares; 2025Q3: 2,308,190 shares; 2025Q4: 2,308,190 shares; 2026Q1: 2,308,190 shares; 2026Q2: 2,308,190 shares 2,308,190$162M30.71%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 772,165 shares; 2025Q1: 772,165 shares; 2025Q2: 772,165 shares; 2025Q3: 772,165 shares; 2025Q4: 772,165 shares; 2026Q1: 772,165 shares; 2026Q2: 772,165 shares 772,165$88.5M16.82%0Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 952,844 shares; 2026Q2: 952,844 shares 952,844$30.7M5.83%0Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,666,666 shares; 2026Q2: 1,666,666 shares 1,666,666$21.7M4.13%0Timeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,739,768 shares 1,739,768$12.8M2.43%newTimeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 272,351 shares 272,351$9.04M1.72%newTimeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 3,545,719 shares; 2025Q1: 3,545,719 shares; 2025Q2: 3,545,719 shares; 2025Q3: 3,545,719 shares; 2025Q4: 3,545,719 shares; 2026Q1: 3,545,719 shares; 2026Q2: 3,545,719 shares 3,545,719$7.13M1.35%0Timeline
EVAXEVAXION ASQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,214,126 shares 1,214,126$3.76M0.71%newTimeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 93,414 shares; 2025Q1: 93,414 shares; 2025Q2: 93,414 shares; 2025Q3: 93,414 shares; 2025Q4: 93,414 shares; 2026Q1: 93,414 shares; 2026Q2: 93,414 shares 93,414$1.72M0.33%0Timeline
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 105,982 shares; 2026Q2: 105,982 shares 105,982$1.02M0.19%0Timeline
HURATUHURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,950 shares; 2025Q3: 13,950 shares; 2025Q4: 13,950 shares; 2026Q1: 19,445 shares; 2026Q2: 19,445 shares 19,445$45.5K0.01%0Timeline
NEUPNEUPHORIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 10,027 shares; 2025Q1: 10,027 shares; 2025Q2: 10,027 shares; 2025Q3: 10,027 shares; 2025Q4: 10,027 shares; 2026Q1: 10,027 shares; 2026Q2: 10,027 shares 10,027$43.8K0.01%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ENTRADA THERAPEUTICS INCENTRADA THERAPEUTICS INC1,739,768$22Mshares
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INC272,351$6.78Mshares
EVAXION BIOTECH A/SEVAXION BIOTECH A/S1,214,126$4.52Mshares
CARMCARISMA THERAPEUTICS INC COM1,473,240$47.9Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000310158-26-000210 base2026-08-07acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0000310158-26-000210 Quarter ended 2026-06-302026-08-07acceptance time not in the bulk data set
13F-HR 0000310158-26-000141 Quarter ended 2026-03-312026-05-13acceptance time not in the bulk data set
13F-HR 0000310158-26-000055 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0000310158-25-000063 Quarter ended 2025-09-302025-11-12acceptance time not in the bulk data set
13F-HR 0001691304-25-000005 Quarter ended 2025-06-302025-08-13acceptance time not in the bulk data set
13F-HR 0000064978-25-000005 Quarter ended 2025-03-312025-05-14acceptance time not in the bulk data set
13F-HR 0000895345-25-000055 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set